Organic compounds -- part of the class 532-570 series – Organic compounds – Carboxylic acid esters
Reexamination Certificate
2006-09-06
2009-11-24
Seaman, D. Margaret (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carboxylic acid esters
Reexamination Certificate
active
07622605
ABSTRACT:
The present invention provides compounds of formula (4), and their pharmaceutically acceptable salts and solvates, which are useful as inhibitors of the Hepatitis C virus (HCV) polymerase enzyme and are also useful for the treatment of HCV infections in HCV-infected mammals. The present invention also provides pharmaceutical compositions comprising compounds of formula (4), their pharmaceutically acceptable salts and solvates. Furthermore, the present invention provides intermediate compounds and methods useful in the preparation of compounds of formula (4).
REFERENCES:
patent: 3786063 (1974-01-01), Arnold
patent: 4326058 (1982-04-01), Okabe et al.
patent: 4489077 (1984-12-01), Sircar et al.
patent: 4591583 (1986-05-01), Helgstrand et al.
patent: 5504104 (1996-04-01), Ellsworth et al.
patent: 5789440 (1998-08-01), Ellsworth et al.
patent: 5808062 (1998-09-01), Domagala et al.
patent: 5834506 (1998-11-01), Boyer, Jr. et al.
patent: 5840751 (1998-11-01), Ellsworth et al.
patent: 5846964 (1998-12-01), Ozeki
patent: 5936128 (1999-08-01), Ellsworth et al.
patent: 6046355 (2000-04-01), Boyer, Jr. et al.
patent: 6174868 (2001-01-01), Anderson et al.
patent: 6512006 (2003-01-01), Boyer, Jr. et al.
patent: 6528510 (2003-03-01), Boyer, Jr. et al.
patent: 7151105 (2006-12-01), Gonzalez et al.
patent: 2003/0171425 (2003-09-01), Boyer, Jr. et al.
patent: 2004/0023958 (2004-02-01), Borchardt et al.
patent: 1 256 628 (2002-11-01), None
patent: WO 95 14011 (1995-05-01), None
patent: WO 95 14012 (1995-05-01), None
patent: WO 98 19997 (1998-05-01), None
patent: WO 0015634 (2000-03-01), None
patent: WO 2004/074270 (2004-09-01), None
Si-Fodil et al., Tetrahedron Letters (1998), 39(49), pp. 8975-8978.
Allen, C.F.H., et al. “The Structure of Certain Polyazaindenes. III. 1,2,3a,7- and 1,3,3a,7-Tetrazaindenes,”J. Org. Chem, 1959, p. 793-796, vol. 24.
Baginski S., et al., “Mechanism of Action of a Pestivirus Antiviral Compound,”Proc. Natl. Acad. Sci. USA, 2000, p. 7981-7986, vol. 97, No. 14.
Bagshawe, K., “Antibody-Directed Enzyme Prodrug Therapy: A Review,”Drug. Development Research, 1995, p. 220-230, vol. 34.
Bartenschlager, R., et al., “Molecular Targets in Inhibition of Hepatitis C Virus Replication”Anitviral Chemistry&Chemotherapy, 1997, p. 281-301, vol. 8, No. 4.
Bartenschlager, R., et al., “Nonstructural Protein 3 of the Hepatitis C Virus Encodes A Serine-Type Proteinase Required for Cleavage At the N53/4 And NS4/5 Junctions,”Journal of Virology, Jul. 1993, p. 3835-3844, vol. 67, No. 7.
Bergman, J., et al, “Synethesis if Chrysogine, a Metabolite ofPenicillium chrysogenumand some related 2-substituted 4-(3H)-Quinazolinones,”Tetrahedron, 1990, p. 1295-1310, vol. 46.
Bertolini, et al., “A New Rational Hypothesis for the Pharmacophore of the Active Metabolite of Leflunomide, a Potent Immunosuppressive Drug,”J. Med. Chem., 1997, p. 2011-2016, vol. 40, issue 13.
Bodor, N, “Novel Approaches to the Design of Safer Drugs: Soft Drugs and Site-Specific Chemical Delivery Systems,”Advances in Drug Research, 1984, p. 255-331, vol. 13.
Boyer, F.E., et al., “5,6-Dihydropyran-2-ones Possessing Various Sulfonyl Functionalities: Potent Nonpeptidic Inhibitors of HIV Protease”,J. Med. Chem., 2000, p. 843-858, vol. 43, No. 5.
Brown, E.A., et al., “Secondary Structure of the 5′Nontranslated Regions of Hepatitis C Virus And Pestivirus Genomic RNAs,”Nucleic Acids Research1992, p. 5041-5045, vol. 20, No. 19.
Bukh, J., et. al., “Sequence Analysis of the 5′ Noncoding Region of Hepatitis C Virus,”Proc. National Academy of Science USA, 1992, p. 4942-4946, vol. 89.
Burke, T.R., et al., “Conformationally Constrained Phosphotyrosyl Mimetics Designed as Monomeric Src Homology 2 Domain Inhibitors,”J. Med. Chem. 1995, p. 1386-1396, vol. 38.
Carvalho, C.F., et al., “Naturally Occurring Dibenzofurans. Part 6. Synthesis of Didymic Acid,”J. Chem Soc. Perkin Trans 1, 1984, p. 1621-1626.
Chavignon, O., et al., “Pyrrolozation Processes of Vinyl Substitued Imidazo[1,2-α]pyridine, Pyrimidine And 1,8-Naphthyridine,”J. Heterocyclic Chem., 1992, p. 691-697, vol. 29.
Choo, Q.-L., et al., “Isolation of a cDNA Clone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis Genome,” Science, Apr. 21, 1989, p. 359-362, vol. 244.
Cuthbert, J., “Hepatitis C: Progress and Problems”Clinical Microbiology Reviews, Oct. 1994, p. 505-532, vol. 7, No. 4.
Dear, G.J., et. al., “Mass Directed Peak Selection, an Efficient Method of Drug Metabolite Identification using Directly Coupled Liquid Chromatography-Mass Spectrometry-Nuclear Magnetic Resonance Spectroscopy,”Journal of Chromatography B, 2000, p. 281-293, vol. 748.
Doria, G., et al, “7-Trans-(2-Pyridylethenyl)-5H-Thiazolo[3,2-a] Pyrimidine-5-Ones: Synthesis and Pharmacological Activity,”Farmaco Ed. Sci., 1985, p. 885-895.
Doyle, M., et al., “Macrocycle Formation by Catalytic Intramolecular Cyclopropanation. A New General Methodology for the Synthesis of Macrolides”Journal of the American Chemical Society, 1997, p. 8826-8837, vol. 19, No. 38.
Earl, R A., et al.,“The preparation of 2(1H)-pyridinones and 2,3-dihydro-5(1H)-indolizinones via transition metal mediated cocyclization of alkynes and isocyanates. A novel construction of the antitumor agent camptothecin,”Journal of Organic Chemistry, 1984, p. 4786-4800, vol. 149.
Ellsworth, E.L., et al., “4 Hydroxy -5,6-Dihydro-2H-Pyran-2-ones. 3. Bicyclic and Hetero-Aromatic Ring Systems as 3-Position Scaffolds to Bind to S1′nd S2′ of the HIV-1 Protease Enzyme,”Bioorg. Med. Chem. Lett., 1999, p. 2019-2024, vol. 9, No. 14.
Ferrari, E., et. al., “Characterization of Soluble Hepatitis C Virus RNA-Dependent RNA Polymerase Expressed inEscherichia coli,” Journal of Virology, 1999, p. 1649-1654, vol. 73, No. 2.
Francki, et al., “Some observations on the Binding Properties of Alfalfa Mosaic Virus to Polystyrene and its significance to indirect ELISA,”Arch. Virol., 1991, p. 219-235, vol. 117.
Gadja, C., et al. “An Efficient Asymmetric Synthesis of Lead Dihydropyrone HIV Protease Inhibitors,”Abstracts of Papers, 37thlnterscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, Sep. 1997, Abstr. I-199b.
Gerecke, M., et al, “New Tetracyclic Derivatives of Imidazo-[1,5-a][1,4]Benzodiazepines and of Imidazo [1,5-a]Thieno[3,2-f][1,4]Diazepines,”Heterocycles, 1994, p. 693-721, vol. 39, No. 2.
Grakoui, A., et al., “Expression And Identification Of Hepatitis C Virus Polyprotein Cleavage Products”Journal Of Virology, Mar. 1993, p. 1385-1395, vol. 67, No. 3.
Hagen, et al., “4-Hydroxy-5,6-dihydropyrones as Inhibitors of HIV Protease: The Effect of Heterocyclic Substituents at C-6 on Antiviral Potency and Pharmacokinetic Parameters”,J. Med. Chem., 2001, p. 2319-2332, vol. 44, No. 14.
Hagen, S., et al., “Synthesis of 5,6-Dihydro-4-hydroxy-2-pyrones as HIV-1 Protease Inhibitors: The Profound Effect of Polarity on Antiviral Activity,”J. Med Chem., 1997, p. 3707-3711, vol. 40, issue 23.
Hénichart, J., et al., “A Convenient Method For The Preparation Of ω-Di-Alkylaminoalkyl Isothiocyanates,”Synthesis, 1980, p. 311-312.
Hijikata, M., et al., “Gene Mapping of the Putative Structural Region of the Hepatitis C Virus Genome by in vitro Processing Analysis”Proc. Natl. Acad. Sci. USA, Jul. 1991, p. 5547-5551, vol. 88.
Hwang, S.B., et al., “Hepatitis C Virus NS5B Protein Is A Membrane-Associated Phosphoprotein With A Predominantly Perinuclear Localization,”Virology, 1997, p. 439-446, vol. 227.
Ishii, et al., “Expression of Hepatitis C Virus NS5B Protein: Characterization of Its RNA Polymerase Activity and RNA Bindint”,Hepatology, 1999, p. 1227-1235, vol. 29, No. 4.
Ishizumi, K., et al.
Gonzalez Javier
Jewell Tanya Michelle
Li Hui
Linton Angelica
Tatlock John Howard
Benson Gregg C.
Creagan B. Timothy
Pfizer Inc.
Rahmani Niloofar
Seaman D. Margaret
LandOfFree
Inhibitors of hepatitis C virus RNA-dependent RNA... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of hepatitis C virus RNA-dependent RNA..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of hepatitis C virus RNA-dependent RNA... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4110309